News & Events about Atreca Inc.
SAN CARLOS, Calif., and MONROVIA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, ...
SAN CARLOS, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced the ...
Atreca, Inc. (NASDAQ:BCEL Get Rating) saw a significant drop in short interest in August. As of August 15th, there was short interest totalling 2,730,000 shares, a drop of 7.8% from the July 31st total of 2,960,000 shares. Approximately 9.7% of the shares of the company are short sold. Based...
Atreca (NASDAQ:BCEL Get Rating) had its price objective dropped by research analysts at Robert W. Baird from $12.00 to $9.00 in a research note issued on Thursday, The Fly reports. Robert W. Bairds price objective suggests a potential upside of 389.13% from the stocks previous close. A number of ...
Ticker Report
10 months ago
Equities research analysts expect Atreca, Inc. (NASDAQ:BCEL Get Rating) to report earnings of ($0.78) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Atrecas earnings, with estimates ranging from ($0.82) to ($0.72). Atreca ...